REPL Replimune Group, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—
Leverage & solvency
Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $221.18M | $189.45M |
| SG&A expense | $98.73M | $72.18M |
| Operating income | -$319.92M | -$261.63M |
| Interest expense | $6.80M | $5.78M |
| Pretax income | -$314.49M | -$246.83M |
| Income tax | -$551,000 | $468,000 |
| Net income | -$313.94M | -$247.30M |
| EBITDA | -$316.59M | -$258.12M |
| EPS (basic) | -3.38 | -3.07 |
| EPS (diluted) | -3.38 | -3.07 |
| Weighted avg. shares (diluted) | 92.80M | 80.56M |
| Balance sheet | ||
| Cash & equivalents | $209.02M | $112.82M |
| Short-term investments | $59.87M | $372.69M |
| Inventory | $0 | — |
| Current assets | $279.12M | $495.88M |
| PP&E, net | $12.97M | $13.74M |
| Total assets | $332.39M | $551.33M |
| Current liabilities | $58.23M | $62.36M |
| Long-term debt | $83.31M | $46.38M |
| Total debt | $83.31M | $46.38M |
| Total liabilities | $166.23M | $135.49M |
| Shareholders' equity | $166.16M | $415.84M |
| Net debt | -$125.72M | -$66.44M |
| Shares outstanding | 82.72M | 77.09M |
| Cash flow statement | ||
| Operating cash flow | -$280.34M | -$192.25M |
| Capital expenditure | $4.22M | $6.69M |
| Free cash flow | -$284.57M | -$198.94M |
| Investing cash flow | $310.84M | -$23.80M |
| Financing cash flow | $66.29M | $252.40M |
| Depreciation & amortization | $3.33M | $3.50M |
| Stock-based compensation | $32.27M | $35.04M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.